Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

被引：0
|
作者：
Kristian Reich
Luca Bianchi
Abdallah Khemis
Julia-Tatjana Maul
Athanasios Tsianakas
Christoph M. Schempp
Kim Petersen
Mia M. Noergaard
Lluis Puig
机构：
[1] University Medical Center Hamburg-Eppendorf,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata,Department of Dermatology, Polyclinique Saint George
[3] Groupe KANTYS,Department of Dermatology
[4] University Hospital of Zürich,Faculty of Medicine
[5] University of Zürich,Department of Dermatology
[6] Fachklinik Bad Bentheim,Department of Dermatology, Faculty of Medicine, Medical Center
[7] University of Freiburg,Department of Dermatology, Hospital de la Santa Creu i Sant Pau
[8] LEO Pharma A/S,undefined
[9] Autonomous University of Barcelona,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷
关键词：
Brodalumab; Guselkumab; Plaque psoriasis; PASI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：453 / 468
页数：15
相关论文
共 50 条
  • [21] Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis
    Feldman, Steven R.
    Reznichenko, Nataliya
    Berti, Fausto
    Duijzings, Paul
    Ruffieux, Ruth
    Otto, Hendrik
    Haliduola, Halimu N.
    Leutz, Steffen
    Stroissnig, Heimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 759 - 771
  • [22] Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2/3 trial
    Nakagawa, Hidemi
    Schenkel, Brad
    Kato, Mai
    Kato, Takeshi
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2012, 39 (09): : 761 - 769
  • [23] Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized double-blind phase 3b clinical trial
    Cather, Jennifer
    Meeuwis, Kim
    Burge, Russel
    Bleakman, Alison Potts
    Lin, Chen-Yen
    Ryan, Caitriona
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB174 - AB174
  • [24] ACITRETIN VERSUS ETRETINATE IN SEVERE PSORIASIS - A DOUBLE-BLIND RANDOMIZED NORDIC MULTICENTER STUDY IN 168 PATIENTS
    BJERKE, JR
    GEIGER, JM
    ACTA-DERMATO-VENEREOLOGICA, SUPPL 146: THIRD EUROPEAN SYMPOSIUM ON PSORIASIS, 1989, : 206 - 207
  • [25] Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
    Merola, Joseph F.
    Parish, Lawrence Charles
    Guenther, Lyn
    Lynde, Charles
    Lacour, Jean -Philippe
    Staubach, Petra
    Cheng, Sue
    Paris, Maria
    Picard, Hernan
    Deignan, Cynthia
    Jardon, Shauna
    Chen, Mindy
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 485 - 493
  • [26] Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study
    Li, Xia
    Ding, Yangfeng
    Zhang, Chunlei
    Lu, Yan
    Li, Fuqiu
    Pan, Weili
    Guo, Shuping
    Li, Jinnan
    Zhao, Bilian
    Zheng, Jie
    ADVANCES IN THERAPY, 2025, 42 (01) : 146 - 163
  • [27] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Wang, Shangshang
    Zhang, Litao
    Liang, Yunsheng
    Zhang, Shifa
    Wang, Jingyan
    Man, Xiaoyong
    Ji, Chao
    Chen, Rixin
    Xiang, Guang
    Meng, Zudong
    Yang, Chunjun
    Cheng, Hao
    Wang, Qi
    Li, Lin-feng
    Zhang, Siping
    Ding, Yanfeng
    Zhu, Quangang
    Qin, Lanying
    Li, Yumei
    Lu, Qianjin
    Xia, Li
    Cao, Shuanglin
    Yu, Chunshui
    Duan, Xinsuo
    Wu, Liming
    Zhang, Chunlei
    Jiang, Congjun
    Wang, Wei
    Xu, Jinhua
    DERMATOLOGIC THERAPY, 2025, 2025 (01)
  • [28] Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
    Tatovic, Danijela
    Marwaha, Ashish
    Taylor, Peter
    Hanna, Stephanie J.
    Carter, Kym
    Cheung, W. Y.
    Luzio, Steve
    Dunseath, Gareth
    Hutchings, Hayley A.
    Holland, Gail
    Hiles, Steve
    Fegan, Greg
    Williams, Evangelia
    Yang, Jennie H. M.
    Domingo-Vila, Clara
    Pollock, Emily
    Wadud, Muntaha
    Ward-Hartstonge, Kirsten
    Marques-Jones, Susie
    Bowen-Morris, Jane
    Stenson, Rachel
    Levings, Megan K.
    Gregory, John W.
    Tree, Timothy I. M.
    Dayan, Colin
    USTEKID Study Gp, Evelien
    NATURE MEDICINE, 2024, 30 (09) : 2657 - 2666
  • [29] Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
    Langley, Richard G.
    Feldman, Steven R.
    Han, Chenglong
    Schenkel, Brad
    Szapary, Philippe
    Hsu, Ming-Chun
    Ortonne, Jean-Paul
    Gordon, Kenneth B.
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (03) : 457 - 465
  • [30] A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease
    Reinisch, Walter
    Panes, Julian
    Lemann, Marc
    Schreiber, Stefan
    Feagan, B.
    Schmidt, Steven
    Sturniolo, Giacomo C.
    Mikhailova, T.
    Alexeeva, Olga
    Sanna, L.
    Haas, T.
    Korom, S.
    Mayer, H.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (09): : 2284 - 2292
12345